Panbela Therapeutics Analyst Ratings
Panbela Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 07/24/2023 | 672.95% | HC Wainwright & Co. | $16 → $16 | Reiterates | Buy → Buy |
| 07/10/2023 | 672.95% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 06/13/2023 | 672.95% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 06/02/2023 | 672.95% | HC Wainwright & Co. | $7 → $16 | Reiterates | → Buy |
| 05/05/2023 | 238.16% | HC Wainwright & Co. | → $7 | Reiterates | → Buy |
| 04/26/2023 | 238.16% | HC Wainwright & Co. | → $7 | Initiates Coverage On | → Buy |
| 03/20/2023 | -27.54% | Maxim Group | → $1.5 | Upgrades | Hold → Buy |
| 01/31/2023 | 383.09% | Roth Capital | → $10 | Reinstates | → Buy |
| 10/12/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 06/28/2021 | 383.09% | Roth Capital | → $10 | Initiates Coverage On | → Buy |
| 03/10/2021 | 286.47% | Maxim Group | → $8 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 07/24/2023 | 672.95% | HC Wainwright公司 | $16→$16 | 重申 | 購買→購買 |
| 07/10/2023 | 672.95% | HC Wainwright公司 | →$16 | 重申 | 購買→購買 |
| 2023/06/13 | 672.95% | HC Wainwright公司 | →$16 | 重申 | 購買→購買 |
| 06/02/2023 | 672.95% | HC Wainwright公司 | $7→$16 | 重申 | →購買 |
| 05/05/2023 | 238.16% | HC Wainwright公司 | →$7 | 重申 | →購買 |
| 04/26/2023 | 238.16% | HC Wainwright公司 | →$7 | 開始承保 | →購買 |
| 03/20/2023 | -27.54% | Maxim集團 | →$1.5 | 升級 | 持有→購買 |
| 2023年年1月31日 | 383.09% | 羅斯資本 | →$10 | 恢復 | →購買 |
| 10/12/2022 | - | Maxim集團 | 評級下調 | 購買→Hold | |
| 2021/06/28 | 383.09% | 羅斯資本 | →$10 | 開始承保 | →購買 |
| 03/10/2021 | 286.47% | Maxim集團 | →$8 | 開始承保 | →購買 |
What is the target price for Panbela Therapeutics (PBLA)?
Panbela治療公司(PBLA)的目標價格是多少？
The latest price target for Panbela Therapeutics (NASDAQ: PBLA) was reported by HC Wainwright & Co. on July 24, 2023. The analyst firm set a price target for $16.00 expecting PBLA to rise to within 12 months (a possible 672.95% upside). 9 analyst firms have reported ratings in the last year.
潘貝拉治療公司(納斯達克：PBLA)的最新目標價是由HC Wainwright&Co.於2023年7月24日報道的。這家分析公司將目標價定為16美元，預計PBLA將在12個月內升至(可能上漲672.95%)。去年有9家分析公司公佈了評級。
What is the most recent analyst rating for Panbela Therapeutics (PBLA)?
Panbela治療公司(PBLA)的最新分析師評級是多少？
The latest analyst rating for Panbela Therapeutics (NASDAQ: PBLA) was provided by HC Wainwright & Co., and Panbela Therapeutics reiterated their buy rating.
潘貝拉治療公司(納斯達克代碼：PBLA)的最新分析師評級由HC Wainwright&Co.提供，潘貝拉治療公司重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for Panbela Therapeutics (PBLA)?
Panbela治療公司(PBLA)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Panbela Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Panbela Therapeutics was filed on July 24, 2023 so you should expect the next rating to be made available sometime around July 24, 2024.
分析師在進行了廣泛的研究後得出了股票評級，其中包括查閱公共財務報表，與Panbela治療公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Panbela治療公司的上一次評級是在2023年7月24日提交的，所以你應該預計下一次評級將在2024年7月24日左右的某個時候提供。
Is the Analyst Rating Panbela Therapeutics (PBLA) correct?
分析師對Panbela Treeutics(PBLA)的評級正確嗎？
While ratings are subjective and will change, the latest Panbela Therapeutics (PBLA) rating was a reiterated with a price target of $16.00 to $16.00. The current price Panbela Therapeutics (PBLA) is trading at is $2.07, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Panbela治療(PBLA)評級被重申，目標價在16.00美元至16.00美元之間。Panbela治療公司(PBLA)目前的交易價格為2.07美元，超出了分析師的預測範圍。